The blood–brain barrier (BBB) remains one of the hardest challenges in biologics development. Designed to protect the central nervous system, it tightly controls which molecules can enter the brain — but this same selectivity prevents many promising therapeutic formats, including antibodies and other large biomolecules, from reaching CNS targets effectively.
In the full article, Isogenica explores why the BBB creates such a significant delivery bottleneck, and how engineered VHH single-domain antibodies may support new approaches to CNS-targeted biologics. VHHs are small, stable and highly engineerable, making them attractive candidates for brain-targeted delivery strategies where specificity, modularity and controlled receptor engagement are important.
The blog examines emerging approaches that use natural transport pathways across the BBB, including receptor-mediated transcytosis. It also explains why design factors such as affinity, valency and pH-dependent binding can materially affect whether a molecule is transported effectively or trapped in the endothelial trafficking pathways.
For teams working on brain-penetrant biologics, the article gives a practical overview of where the field is heading — and why synthetic VHH discovery could play a role in developing more precise, engineerable and translationally relevant CNS-targeting strategies.
Read the full blog: https://isogenica.com/vhh-and-the-blood-brain-barrier-challenge/